Slovakia-based contract development and manufacturing organization (CDMO) Saneca Pharma has added senior talent to its team to position the company for its next phase of growth.
With a background in the pharmaceutical contract services industry spanning more than 20 years, Jeremy Drummond joins the CDMO as Sales and Marketing Director.
Jeremy will be focused on growing Saneca Pharma’s active pharmaceutical ingredient (API) and finished dosage form development and manufacturing business in Europe and North America.
Juraj Kubáň also joins the CDMO in the role of Project Development Manager. With a background in pharmaceutical project management and a PhD in organic chemistry, Juraj will assist Saneca Pharma’s customers with the efficient transfer of products from API through to finished dosage form.
Anthony Sheehan, CEO at Saneca Pharma said: “Our site has a strong big pharma heritage, with more than 70 years of expertise in producing APIs and finished dosage forms. Following the company’s transition to CDMO, a key focus is to ensure the market and customers understand what makes the Saneca Pharma offering different. Adding the likes of Jeremy and Juraj to our senior management team underlines our commitment to be the outsourcing partner of choice for pharmaceutical companies in need of a technically agile and responsive CDMO. Both have exceptional experience in the contract services sector that will help ensure we compete with the biggest CMOs and CDMOs across the globe.”
From its site in Hlohovec, Slovakia, Saneca Pharma provides full service development and manufacturing capabilities for APIs and finished dosage forms. With particular expertise in controlled substances, the CDMO can produce opiate products from ‘farm to pharmacy,’ simplifying the supply chain for its customers.
Jeremy said: “As the biggest pharmaceutical company in Slovakia with significant growth plans for the contract manufacturing business, it’s an exciting time to join Saneca. We are well positioned to offer a fully integrated drug development, manufacturing and supply service thanks to the range of technologies and quality of pharmaceutical expertise found on our site. We expect to experience steady growth in the coming months as our team has the technical agility to handle multi-step products, complex molecules, novel release mechanisms and patient compliance challenges; services that are in demand in today’s market.”